Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Richard (Rick) JaeBong Lee, MD, PhD
Advertisement
Articles by Richard (Rick) JaeBong Lee, MD, PhD
Advertisement
Latest Updated Articles
Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPCPublished: April 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
2
Five Under 5: Top Oncology Videos for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
The OncFive: Top Oncology Articles for the Week of 1/25
5